The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: Design and rationale of the CONTRAST-AMI study

Journal of Cardiovascular Medicine

Volumn 11, Issue 3, 2010, Pages 199-206

  Bolognese, Leonardo ^a   Falsini, Giovanni ^a   Grotti, Simone ^a   Limbruno, Ugo ^b   Liistro, Francesco ^a   Carrera, Arcangelo ^c   Angioli, Paolo ^a   Picchi, Andrea ^b   Ducci, Kenneth ^a   Pierli, Carlo ^c  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Acute myocardial infarction; Contrast agents; Nephrotoxicity; Primary angioplasty

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; IODIXANOL; IOPROMIDE;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HEART MUSCLE REVASCULARIZATION; HEART PERFUSION; HUMAN; KIDNEY INJURY; LENGTH OF STAY; LOADING DRUG DOSE; MALE; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACETYLCYSTEINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; HEART DISEASES; HUMANS; IOHEXOL; ITALY; KIDNEY FAILURE, ACUTE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RESEARCH DESIGN; SINGLE-BLIND METHOD; SYNDROME; TIME FACTORS; TREATMENT OUTCOME; TRIIODOBENZOIC ACIDS;

EID: 76449087389     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32833186a4     Document Type: Article

References (55)

1. McCullough PA, Wolyn R, Rocher LL, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368-375.
2. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol 2004; 44:1343-1353.
3. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93:1515-1519.
4. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44:1393-1399.
5. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264.
6. Weisbord SD, Hartwig KC, Sonel AF, Hartwig KC, Palevsky PM, Fine MJ, et al. The incidence of clinically significant contrast-induced nephropathy following non-emergent coronary angiography. Catheter Cardiovasc Interv 2008; 71:879-885.
7. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997; 203:605-610.
8. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320:143-149.
9. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990; 150:1237-1242.
10. Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int 2006; 69:S8-S10.
11. Persson PB, Hansell P, Liss P. Pathophysiology of contrast mediuminduced nephropathy. Kidney Int 2005; 68:14-22.
12. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol 1983; 141:1027-1033.
13. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003; 4 (Suppl 5):S3-S9.
14. Weisz G, Mehran R, Rabbani L, Rabbani L, Kornowski R, Hartmann F, et al. Contrast-induced nephropathy is frequent and is a powerful independent predictor of morbidity and mortality in patients with acute myocardial infarction treated with primary PCI: the HORIZONS-AMI trial. Late- Breaking clinical Trial Session at The TCT 2008 Annual Scientific Session in Washington; 2008.
15. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004; 44:1780-1785.
16. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354:2773-2782.
17. Recio-Mayoral A, Chaparro M, Prado B, Có zar R, Mé ndez I, Banerjee D, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007; 49:1283-1288.
18. Chong E, Poh K, Shen L, Soon C, Ong H, Tan H. Comparison of risks and clinical predictors of contrast induced nephropathy in patients undergoing emergency versus non-emergency percutaneous coronary interventions. Late-Breaking clinical Trial Session at The TCT 2008 Annual Scientific Session in Washington; 2008.
19. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188:171-178.
20. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47:254-261.
21. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499.
22. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72:701-703.
23. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study - a randomized controlled trial. J Am Coll Cardiol 2006; 48:924-930.
24. Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2005; 68:2250-2255.
25. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF, VALOR Trial Investigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008; 156:776-782.
26. Sahani DV, Soulez G, Chen KM, Lepanto L, Xu JR, Nelson RC, et al. A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography. Invest Radiol 2007; 42:856-861.
27. Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, et al. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 2008; 43:170-178.
28. Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, So GJ. The PREDICT study: a randomized double-blind comparison of contrastinduced nephropathy after low- or iso-osmolar contrast agent exposure. AJR Am J Roentgenol 2008; 191:151-157.
29. Carraro M, Malalan F, Antonione R, Stacul F, Cova M, Petz S, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 1998; 8:144-147.
30. Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006; 41:815-821.
31. Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, et al. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology 2008; 248:97-105.
32. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007; 115:3189-3196.
33. Wessely R, Kumar K. Randomized clinical trial to compare the nephrotoxic effects of iso-osmolar versus low-osmolar contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention: The COntrast Media and NephroToxicity Following Coronary Revascularization by AngioplaSTy (CONTRAST) Study. ACC Annual Scientific Session 2008.
34. From AM, Bartholmai BJ, Williams AW, McDonald FS. Iodixanol compared to iohexol for contrast procedures: a case-matched retrospective cohort study. Acta Radiol 2008; 49:409-414.
35. Heinrich MC, Haberle L, Muller V, Bautz W, Uder M. Nephrotoxicity of isoosmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 2009; 250:68-86.
36. Baile EM, Paré PD, D'yachkova Y, Carere RG. Effect of contrast media on coronary vascular resistance: contrast-induced coronary vasodilation. Chest 1999; 116:1039-1045.
37. Sheu SH, Hwang MH, Piao ZE, Hariman RJ, Loeb HS, Scanlon PJ. Effects of intracoronary administration of contrast media on coronary hemodynamics in a canine post ischemic reperfusion model. Cathet Cardiovasc Diagn 1991; 23:144-149.
38. Sheu SH, Hwang MH, Piao ZE, Hariman RJ, Louie EK, Loeb HS. Effects of contrast media on coronary hemodynamics and myocardial metabolism. Invest Radiol 1995; 30:28-32.
39. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116:e148-e304.
40. KDOQI. KDOQI Clinical practice guidelines for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (Suppl 2):S12-S154.
41. Rudnick MR, Tumlin JA. Prevention of radiocontrast media-induced acute kidney injury (acute renal failure). UpToDate 2007 version 15.2.
42. Benko A, Fraser-Hill M, Magner P, Capusten B, Barrett B, Myers A, et al. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. Can Assoc Radiol J 2007; 58:79-87.
43. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180-184.
44. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, et al. N-Acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004; 15:761-769.
45. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41:2114-2118.
46. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25:206-211.
47. Meyer M, LeWinter MM, Bell SP, F Chen Z. Selby DE, Singla DK, Dauerman HL. N-Acetylcysteine-enhanced contrast provides cardiorenal protection. JACC Cardiovasc Interv 2009; 2:215-221.
48. Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. N-Acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 1995; 92:2855-2862.
49. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
50. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93:879-888.
51. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312:932-936.
52. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation 1999; 99:1945-1950.
53. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101:125-130.
54. Bolognese L, Ducci K, Angioli P, Falsini G, Liistro F, Baldassarre S, Burali A. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2004; 110:1592-1597.
55. Tarantini G, Ramondo A, Napodano M, Bilato C, Isabella G, Razzolini R, Iliceto S. Myocardial perfusion grade and survival after percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. Am J Cardiol 2004; 93:1081-1085.